Compile Data Set for Download or QSAR
Report error Found 25 Enz. Inhib. hit(s) with all data for entry = 9324
TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458369(US10752626, Compound 31)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458368(US10752626, Compound 24)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458367(US10752626, Compound 23)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458366(US10752626, Compound 22)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458365(US10752626, Compound 21)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458363(US10752626, Compound 19)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458362(US10752626, Compound 18)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458361(US10752626, Compound 17)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458360(US10752626, Compound 16)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458359(US10752626, Compound 15)
Affinity DataIC50: 1.50E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458364(US10752626, Compound 20)
Affinity DataIC50: 5.75E+3nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458357(US10752626, Compound 13)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458358(US10752626, Compound 14)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458345(US10752626, Compound 1)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458356(US10752626, Compound 12)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458355(US10752626, Compound 11)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458354(US10752626, Compound 10)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458353(US10752626, Compound 9)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458352(US10752626, Compound 8)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458351(US10752626, Compound 7)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458350(US10752626, Compound 6)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458349(US10752626, Compound 5)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458348(US10752626, Compound 4)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458347(US10752626, Compound 3)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent

TargetIsocitrate dehydrogenase [NADP] cytoplasmic [R132C](Human)
Shanghai Meton Pharmaceutical

US Patent
LigandPNGBDBM458346(US10752626, Compound 2)
Affinity DataIC50: 1.25E+4nMAssay Description:Solution A was prepared by combining 1 M Tris-HCl pH7.5 (300 μL), 5 M NaCl (450 μL), 1 M MgCl2 (150 μL), 1 M DTT (15 μL), 20 mg/m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/11/2021
Entry Details
Go to US Patent